课题基金 / 基金详情

THERAPEUTIC ROLE OF FERRITIN IN NEUROBLASTOMA

THERAPEUTIC ROLE OF FERRITIN IN NEUROBLASTOMA
铁蛋白在神经母细胞瘤中的治疗作用
批准号:
3476923
负责人:
JULIE BLATT
金额:
$7.69万
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-07-01 至 1990-06-30

项目摘要

项目成果

JULIE BLATT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Ferritin is an iron-storage protein that is found in normal human serum. Greater than normal serum levels are found in some patients with neuroblastoma and predict a poor outcome. Indirect evidence suggests that ferritin in these patients may be synthesized by their tumor cells. In an attempt to understand why ferritin levels correlate with prognosis, studies have focused on the ability of ferritin to inhibit host immune responses and thereby enhance tumor growth. It is postulated that in addition to these effects, ferritin or the ferric ions that it carries may function as a growth factor for neuroblastoma and directly contribute to tumor growth. As a correlary it is postulated that chelation of iron may provide an approach to the treatment of neuroblastoma. Preliminary data suggest that desferoxamine, a high affinity iron chelator which can extract iron from ferritin, kills growing neuroblastoma cells in vitro. To further explore the biological role of ferritin in neuroblastoma as well as the mechanism by which desferoxamine kills neuroblastoma cells, it is proposed: to establish that neuroblastoma cells can synthesize ferritin; to determine whether ferritin potentiates nucleic acid or protein synthesis by neuroblastoma cells in serum-free medium; and to study the ability of neuroblastoma cells to bind ferritin in the manner of known growth factors. In addition the effect of desferoxamine on tumor cell lines with respect to DNA, RNA and protein synthesis, cell cycling, and activity of iron-dependent cellular enzymes will be studied. Finally, utilizing available toxicity data, a phase II clinical trial of desferoxamine in children with end-stage neuroblastoma and other malignancies will be conducted.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STUDY OF SELECTED LATE EFFECTS IN PATIENTS TREATED FOR NONHODGKINS LYMPHOMA
PEDIATRIC PHASE I TRIAL AND PHARMACOKINETIC STUDY OF LGC1057
PHASE I STUDY OF TOPOTECAN AND CISPLATIN IN THE TREATMENT OF SOLID TUMORS
THERAPEUTIC ROLE OF FERRITIN IN NEUROBLASTOMA
国内基金
海外基金
免标记CRISPR-RNA适配体与门逻辑分子诊断新方法研究
  • 批准号:
    2026JJ50010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    应站明
  • 依托单位:
RNA m6A修饰通过调控FDX1介导的铜死亡参与补阳还五汤抗脑缺血再灌注损伤作用机制的研究
  • 批准号:
    2026JJ81091
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    刘亮
  • 依托单位:
基于合成生物标志物的超多重RNA数字化检测平台用于肿瘤精准诊断和分期评估
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    程子译
  • 依托单位:
Dead-box解旋酶DDX23通过调控RNA高级结构促进肝癌细胞恶性生物学行为的分子机制研究
  • 批准号:
    JCZRLH202600588
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位: